The Cleveland Cord Blood Center (CCBC) is in the midst of one of the most exciting times in our history! We can truly say that we’re pursuing new opportunities reflective of our mission at a pace that we could never have predicted. 

  • Our newest collection site at Kaiser Permanente San Leandro Medical Center in the East Bay area of California is expanding our ability to collect a broader diversity of cord blood units to help meet growing national and worldwide demand. 
  • The Cleveland Cell Therapy Incubator (CCTI) recently entered into an agreement with European-based Glycostem Therapeutics. As an FDA-licensed U.S. cord blood bank for sourcing material, CCTI is engaging with new partners on future development programs.
  • Wouter Van’t Hof, Director, Cord Blood Bank and CEO, Cleveland Cell Therapy Incubator, has been invited to attend the FDA’s Cell Therapy Liaison Meeting for a discussion of the alignment of global requirements for development and approval of cell therapies in the U.S. and internationally.
  • Helping to cultivate new leaders in the Next Gen cellular therapy arena, we shared insights with the Case Western Reserve University (CWRU) National Center for Regenerative Medicine’s Entrepreneurial Biotechnology graduate students.
  • Executive Director Marcie Finney was honored to present at the Cord Blood Connect International Congress in September at which she shared CCBC’s perspective on U.S. Public Bank Sustainability Strategies.
  • We invite you to read on about how Next Gen growth opportunities are unfolding for the Cleveland Cord Blood Center in our contributions to advance umbilical cord blood cell therapy treatments, one birth at a time.